Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Pilot Study of Video and Telephone Primary Care Visits

8 février 2022 mis à jour par: Johns Hopkins University

Pilot Study - Randomized Controlled Trial of Video and Telephone Primary Care Visits

The inability to access and use smartphones or camera-outfitted internet-connected devices during the COVID-19 pandemic relegates certain patients to receive audio-only telemedicine instead of audio/video-based telemedicine. The investigators are conducting a randomized controlled trial in order to characterize patient and provider attitudes towards these two modalities of care and to test the feasibility of a new model to make tablets for video-based care accessible to those who need that. The investigators hypothesize that patient and provider satisfaction will be higher with video-based telehealth when compared to phone-based telehealth.

Aperçu de l'étude

Statut

Complété

Les conditions

Type d'étude

Interventionnel

Inscription (Réel)

15

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Maryland
      • Baltimore, Maryland, États-Unis, 21287
        • Johns Hopkins Outpatient Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult patients scheduled for telephone-based visits who are doing so because of a lack of ability to conduct a video visit (i.e. no tablet/laptop; no access to internet) who live in Baltimore City

Exclusion Criteria:

  • Patients with significant visual or hearing impairment
  • Patients that have legal guardians or who are marked as lacking healthcare decision-making capacity
  • Patients that have not selected English as their preferred language

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Telemedicine - Phone
Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
Expérimental: Telemedicine - Audio/Video
Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Provider rating as assessed by the Consumer Assessment of Healthcare Providers and Systems question on provider rating
Délai: Within 2 weeks of the study visit
Provider rating will be assessed with the Consumer Assessment of Healthcare Providers and Systems question on provider rating of 0-10; 0 being worst provider possible and 10 being best provider possible.
Within 2 weeks of the study visit

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Satisfaction with telemedicine visit for patient as assessed by a Likert scale
Délai: Within 2 weeks of the study visit

Satisfaction with telemedicine visit for patient will be assessed with Likert-scale questions related to satisfaction.

Satisfaction (1=strongly disagree to 5=strongly agree).

  1. In general, I was satisfied with using a video or phone call for this visit
  2. I could explain my medical problems well enough
  3. Talking to the doctor was as satisfying as talking in person

Overall score 3 to 15 with higher scores signifying better satisfaction.

Within 2 weeks of the study visit
Satisfaction with telemedicine visit for provider as assessed by a Likert scale
Délai: Within 2 weeks of the study visit

Satisfaction with telemedicine visit for provider will be assessed with Likert-scale questions related to satisfaction.

[1=Strongly Disagree. 5=Strongly Agree].

  1. In general, I was satisfied with using telemedicine for this visit
  2. Talking to the patient was as satisfying as talking in person.

Overall score 2 to 10 with higher scores signifying better satisfaction.

Within 2 weeks of the study visit
Efficacy of telemedicine visit for provider as assessed by a Likert scale
Délai: Within 2 weeks of the study visit

Efficacy of telemedicine visit for provider will be assessed with Likert-scale questions related to efficacy.

[1=Strongly Disagree. 5=Strongly Agree]. b. I was able to understand the patient's explanation of their medical problems well enough.

c. In general, this telemedicine visit was effective in improving this patient's medical care d. An in-person visit would likely have provided additional clinically-relevant information e. An in-person visit would likely have led to a change in management

Within 2 weeks of the study visit
Provider communication as assessed by yes/no question
Délai: Within 2 weeks of the study visit

The ability of a provider to communicate will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire related to communication.

Did this provider explain things in a way that was easy to understand? Yes/No

Within 2 weeks of the study visit
Provider listening as assessed by yes/no question
Délai: Within 2 weeks of the study visit

Provider listening will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire related to listening.

Did this provider listen carefully to you? Yes/No

Within 2 weeks of the study visit
Provider respect as assessed by yes/no question
Délai: Within 2 weeks of the study visit

Provider respect will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire relating to respect.

Did this provider show respect for what you had to say? Yes/No

Within 2 weeks of the study visit
Provider time spent as assessed by yes/no question
Délai: Within 2 weeks of the study visit

Provider time spent will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire relating to time spent during the clinical encounter.

Did this provider spend enough time with you? Yes/No

Within 2 weeks of the study visit
Patient health rating as assessed by a likert scale
Délai: Within 2 weeks of the study visit

Patient health will be assessed with Likert-scale questions related to patient health.

In general, how would you rate your overall health?

  1. Excellent
  2. Very good
  3. Good
  4. Fair
  5. Poor

In general, how would you rate your overall mental or emotional health?

  1. Excellent
  2. Very good
  3. Good
  4. Fair
  5. Poor

Overall score 2 to 10 with lower scores signifying better health.

Within 2 weeks of the study visit

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Jeremy A Epstein, MD, Johns Hopkins University
  • Chercheur principal: Casey Overby Taylor, PhD, Johns Hopkins University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

24 janvier 2021

Achèvement primaire (Réel)

24 novembre 2021

Achèvement de l'étude (Réel)

30 décembre 2021

Dates d'inscription aux études

Première soumission

29 juillet 2020

Première soumission répondant aux critères de contrôle qualité

29 juillet 2020

Première publication (Réel)

3 août 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 février 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 février 2022

Dernière vérification

1 février 2021

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IRB00257994

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Protocol and analysis plan, without any protected health information (PHI), can be shared on request via email.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner